NCT04126369 Impact of Mindfulness Intervention on Quality of Life in Patients With Drug-resistant Epilepsy.
| NCT ID | NCT04126369 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital, Grenoble |
| Condition | Drug Resistant Epilepsy |
| Study Type | INTERVENTIONAL |
| Enrollment | 100 participants |
| Start Date | 2020-01-20 |
| Primary Completion | 2026-01-20 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 100 participants in total. It began in 2020-01-20 with a primary completion date of 2026-01-20.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study evaluates a mindfulness intervention in patients with drug resistant epilepsy. Half of participants will follow a mindfulness programme, while the other half will follow a self management programme.
Eligibility Criteria
Inclusion Criteria: * Drug resistant epilepsy according to the criteria of the International League Against Epilepsy (ILAE) * Stable therapy for at least 3 months * No planned surgery * Patient affiliated to social security insurance or beneficiary of social security insurance. * Signed consent Exclusion Criteria: * Patient who has previously had or regularly practicing mindfulness * Patient with psychogenic non-epileptic seizures * Pregnant woman, breastfeeding mother, person deprived of liberty by judicial or administrative decision, person subject to legal protection * Patient with relationship disorders related to psychosis * Patients who are unable or unwilling to work as a group or person unable to understand the topics discussed during session.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT04126369 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Drug Resistant Epilepsy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04126369 currently recruiting?
Yes, NCT04126369 is actively recruiting participants. Contact the research team at CSabourdy@chu-grenoble.fr for enrollment information.
Where is the NCT04126369 trial being conducted?
This trial is being conducted at Grenoble, France, Lyon, France, Tain-l'Hermitage, France.
Who is sponsoring the NCT04126369 clinical trial?
NCT04126369 is sponsored by University Hospital, Grenoble. The trial plans to enroll 100 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.